Header Logo

Connection

Allison Naleway to Adolescent

This is a "connection" page, showing publications Allison Naleway has written about Adolescent.
Connection Strength

3.682
  1. Temporal trends in Tdap vaccination coverage during pregnancy in the Vaccine Safety Datalink, 2016 through 2023. Vaccine. 2026 Nov 14; 93:129175.
    View in: PubMed
    Score: 0.139
  2. 2023-2024 COVID-19 vaccination coverage in pregnancy in ten healthcare delivery organizations in the United States. Vaccine. 2026 Apr 19; 79:128441.
    View in: PubMed
    Score: 0.134
  3. Differences in influenza vaccination coverage by race and ethnicity across age groups in the Vaccine Safety Datalink, 2017-18 through 2022-23 influenza seasons. Vaccine. 2025 Oct 03; 64:127667.
    View in: PubMed
    Score: 0.129
  4. Parental intent to vaccinate children with the updated 2023-2024 COVID-19 vaccine. Vaccine. 2025 Sep 17; 63:127618.
    View in: PubMed
    Score: 0.129
  5. Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years. JAMA. 2024 02 06; 331(5):408-416.
    View in: PubMed
    Score: 0.116
  6. Incidence of SARS-CoV-2 Infection, Emergency Department Visits, and Hospitalizations Because of COVID-19 Among Persons Aged =12 Years, by COVID-19 Vaccination Status - Oregon and Washington, July 4-September 25, 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 19; 70(46):1608-1612.
    View in: PubMed
    Score: 0.099
  7. Incidence of pediatric inflammatory bowel disease within the Vaccine Safety Datalink network and evaluation of association with rotavirus vaccination. Vaccine. 2021 06 16; 39(27):3614-3620.
    View in: PubMed
    Score: 0.096
  8. Temporal Trends in the Incidence of Anogenital Warts: Impact of Human Papillomavirus Vaccination. Sex Transm Dis. 2020 03; 47(3):179-186.
    View in: PubMed
    Score: 0.088
  9. Uptake and safety of hepatitis A vaccination during pregnancy: A Vaccine Safety Datalink study. Vaccine. 2019 10 16; 37(44):6648-6655.
    View in: PubMed
    Score: 0.085
  10. Uptake and safety of Hepatitis B vaccination during pregnancy: A Vaccine Safety Datalink study. Vaccine. 2018 10 01; 36(41):6111-6116.
    View in: PubMed
    Score: 0.079
  11. Feasibility of a pilot intervention to reduce pain and syncope during adolescent vaccination. Vaccine. 2018 06 22; 36(27):3937-3942.
    View in: PubMed
    Score: 0.078
  12. Implementing a Multipartner HPV Vaccination Assessment and Feedback Intervention in an Integrated Health System. J Public Health Manag Pract. 2017 Nov/Dec; 23(6):589-592.
    View in: PubMed
    Score: 0.075
  13. Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008-2011. Vaccine. 2016 Jan 02; 34(1):167-71.
    View in: PubMed
    Score: 0.065
  14. Pregnancy after treatment for cervical cancer precursor lesions in a retrospective matched cohort. PLoS One. 2015; 10(2):e0117525.
    View in: PubMed
    Score: 0.062
  15. Evaluation of a surveillance case definition for anogenital warts, Kaiser Permanente northwest. Sex Transm Dis. 2014 Aug; 41(8):496-500.
    View in: PubMed
    Score: 0.060
  16. Monovalent H1N1 influenza vaccine safety in pregnant women, risks for acute adverse events. Vaccine. 2014 Sep 03; 32(39):4985-92.
    View in: PubMed
    Score: 0.060
  17. Barriers and facilitators to influenza vaccination and vaccine coverage in a cohort of health care personnel. Am J Infect Control. 2014 Apr; 42(4):371-5.
    View in: PubMed
    Score: 0.058
  18. Vaccinations given during pregnancy, 2002-2009: a descriptive study. Am J Prev Med. 2014 Feb; 46(2):150-7.
    View in: PubMed
    Score: 0.058
  19. Uptake, coverage, and completion of quadrivalent human papillomavirus vaccine in the vaccine safety Datalink, July 2006-June 2011. J Adolesc Health. 2013 Nov; 53(5):637-41.
    View in: PubMed
    Score: 0.057
  20. Identifying pregnancy episodes, outcomes, and mother-infant pairs in the Vaccine Safety Datalink. Vaccine. 2013 Jun 12; 31(27):2898-903.
    View in: PubMed
    Score: 0.055
  21. Reported adverse events in young women following quadrivalent human papillomavirus vaccination. J Womens Health (Larchmt). 2012 Apr; 21(4):425-32.
    View in: PubMed
    Score: 0.050
  22. Frequency of medically attended events following rapid revaccination with trivalent inactivated influenza vaccine. Vaccine. 2010 Nov 16; 28(49):7713-5.
    View in: PubMed
    Score: 0.046
  23. Risk of immune hemolytic anemia in children following immunization. Vaccine. 2009 Dec 09; 27(52):7394-7.
    View in: PubMed
    Score: 0.043
  24. Household Transmission of SARS-CoV-2 in Washington and Oregon, United States, 2022-2024. J Pediatric Infect Dis Soc. 2026 Aug 04; 15(8).
    View in: PubMed
    Score: 0.034
  25. Immune correlates of risk for SARS-CoV-2 infection in children: a prospective, community-based cohort study. Nat Commun. 2026 Jul 18; 17(1).
    View in: PubMed
    Score: 0.034
  26. Influenza Activity and Estimated Vaccine Effectiveness During the 2025-2026 Influenza Season. JAMA Netw Open. 2026 Jun 01; 9(6):e2618581.
    View in: PubMed
    Score: 0.034
  27. Interim Estimated Effectiveness of 2025-2026 COVID-19 Vaccines in Adults Using a Test-Negative Design. JAMA Netw Open. 2026 Jun 01; 9(6):e2625152.
    View in: PubMed
    Score: 0.034
  28. Influenza household transmission and genomic diversity in the United States: A prospective cohort study, 2022-2024. J Infect. 2026 May; 92(5):106748.
    View in: PubMed
    Score: 0.034
  29. Estimated Burden of COVID-19 Illnesses, Medical Visits, Hospitalizations, and Deaths in the US From October 2022 to September 2024. JAMA Intern Med. 2026 03 01; 186(3):321-330.
    View in: PubMed
    Score: 0.033
  30. Effectiveness of 2024-2025 COVID-19 Vaccines in Children in the United States - VISION, August 29, 2024-September 2, 2025. MMWR Morb Mortal Wkly Rep. 2025 Dec 11; 74(40):607-614.
    View in: PubMed
    Score: 0.033
  31. Effectiveness of 2023-2024 Coronavirus Disease 2019 (COVID-19) Vaccines in Pregnant Women. Obstet Gynecol. 2026 Apr 01; 147(4):569-573.
    View in: PubMed
    Score: 0.033
  32. Correlates of risk of respiratory syncytial virus disease: a prospective cohort study. Nat Commun. 2025 Sep 26; 16(1):8490.
    View in: PubMed
    Score: 0.032
  33. Effectiveness of 2023-2024 seasonal influenza vaccine against influenza-associated emergency department and urgent care encounters among pregnant and non-pregnant women of reproductive age. Vaccine. 2025 Aug 30; 62:127483.
    View in: PubMed
    Score: 0.032
  34. Epidemiology of Symptomatic Human Metapneumovirus Infection in the CASCADIA Community-Based Cohort - Oregon and Washington, 2022-2024. MMWR Morb Mortal Wkly Rep. 2025 Apr 03; 74(11):188-193.
    View in: PubMed
    Score: 0.031
  35. Interim Estimates of 2024-2025 COVID-19 Vaccine Effectiveness Among Adults Aged =18 Years - VISION and IVY Networks, September 2024-January 2025. MMWR Morb Mortal Wkly Rep. 2025 Feb 27; 74(6):73-82.
    View in: PubMed
    Score: 0.031
  36. COVID-19 Vaccination and Odds of Post-COVID-19 Condition Symptoms in Children Aged 5 to 17 Years. JAMA Netw Open. 2025 Feb 03; 8(2):e2459672.
    View in: PubMed
    Score: 0.031
  37. Epidemiology of systemic lupus erythematosus in rural Wisconsin. Lupus. 2005; 14(10):862-6.
    View in: PubMed
    Score: 0.031
  38. Disparities in COVID-19 vaccination receipt by race, ethnicity, and social determinants of health among a large patient population in a network of community-based healthcare centers. Vaccine. 2024 Oct 24; 42(24):126288.
    View in: PubMed
    Score: 0.030
  39. Influenza Vaccine Effectiveness Against Influenza A-Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022-2023. J Infect Dis. 2024 Jul 25; 230(1):141-151.
    View in: PubMed
    Score: 0.030
  40. Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged =18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024. MMWR Morb Mortal Wkly Rep. 2024 Mar 28; 73(12):271-276.
    View in: PubMed
    Score: 0.029
  41. Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged =18 Years - VISION and IVY Networks, September 2023-January 2024. MMWR Morb Mortal Wkly Rep. 2024 Feb 29; 73(8):180-188.
    View in: PubMed
    Score: 0.029
  42. Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines. Vaccine. 2023 09 07; 41(39):5678-5682.
    View in: PubMed
    Score: 0.028
  43. Eczematous skin disease and recall of past diagnoses: implications for smallpox vaccination. Ann Intern Med. 2003 Jul 01; 139(1):1-7.
    View in: PubMed
    Score: 0.028
  44. Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023. MMWR Morb Mortal Wkly Rep. 2023 May 26; 72(21):579-588.
    View in: PubMed
    Score: 0.028
  45. Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents. Pediatrics. 2023 05 01; 151(5).
    View in: PubMed
    Score: 0.027
  46. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022. MMWR Morb Mortal Wkly Rep. 2023 Mar 17; 71(53):1637-1646.
    View in: PubMed
    Score: 0.027
  47. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022. MMWR Morb Mortal Wkly Rep. 2022 Dec 30; 71(5152):1616-1624.
    View in: PubMed
    Score: 0.027
  48. Extended surveillance to assess safety of 9-valent human papillomavirus vaccine. Hum Vaccin Immunother. 2022 12 30; 18(7):2159215.
    View in: PubMed
    Score: 0.027
  49. Receipt of COVID-19 Booster Dose Among Fully Vaccinated Pregnant Individuals Aged 18 to 49 Years by Key Demographics. JAMA. 2022 06 21; 327(23):2351-2354.
    View in: PubMed
    Score: 0.026
  50. Lyme disease incidence in Wisconsin: a comparison of state-reported rates and rates from a population-based cohort. Am J Epidemiol. 2002 Jun 15; 155(12):1120-7.
    View in: PubMed
    Score: 0.026
  51. Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022. MMWR Morb Mortal Wkly Rep. 2022 Apr 01; 71(13):495-502.
    View in: PubMed
    Score: 0.025
  52. Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022. MMWR Morb Mortal Wkly Rep. 2022 Mar 18; 71(11):422-428.
    View in: PubMed
    Score: 0.025
  53. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Mar 04; 71(9):352-358.
    View in: PubMed
    Score: 0.025
  54. Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1539-1544.
    View in: PubMed
    Score: 0.025
  55. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1553-1559.
    View in: PubMed
    Score: 0.025
  56. Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19-Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance - Nine States, June-August 2021. MMWR Morb Mortal Wkly Rep. 2021 09 17; 70(37):1291-1293.
    View in: PubMed
    Score: 0.024
  57. COVID-19 Vaccination Coverage Among Insured Persons Aged =16 Years, by Race/Ethnicity and Other Selected Characteristics - Eight Integrated Health Care Organizations, United States, December 14, 2020-May 15, 2021. MMWR Morb Mortal Wkly Rep. 2021 Jul 16; 70(28):985-990.
    View in: PubMed
    Score: 0.024
  58. Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. N Engl J Med. 2021 07 22; 385(4):320-329.
    View in: PubMed
    Score: 0.024
  59. COVID-19 Vaccination Coverage Among Pregnant Women During Pregnancy - Eight Integrated Health Care Organizations, United States, December 14, 2020-May 8, 2021. MMWR Morb Mortal Wkly Rep. 2021 Jun 18; 70(24):895-899.
    View in: PubMed
    Score: 0.024
  60. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021. MMWR Morb Mortal Wkly Rep. 2021 Apr 02; 70(13):495-500.
    View in: PubMed
    Score: 0.024
  61. Evaluating the Association of Stillbirths After Maternal Vaccination in the Vaccine Safety Datalink. Obstet Gynecol. 2020 12; 136(6):1086-1094.
    View in: PubMed
    Score: 0.023
  62. SARS-CoV-2 Infection Among Hospitalized Pregnant Women: Reasons for Admission and Pregnancy Characteristics - Eight U.S. Health Care Centers, March 1-May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020 Sep 23; 69(38):1355-1359.
    View in: PubMed
    Score: 0.023
  63. Epidemiology and Clinical Outcomes of Hospitalizations for Acute Respiratory or Febrile Illness and Laboratory-Confirmed Influenza Among Pregnant Women During Six Influenza Seasons, 2010-2016. J Infect Dis. 2020 04 27; 221(10):1703-1712.
    View in: PubMed
    Score: 0.022
  64. Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine. Pediatrics. 2019 12; 144(6).
    View in: PubMed
    Score: 0.022
  65. Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink in 2012-13, 2013-14, and 2014-15. Vaccine. 2019 10 16; 37(44):6673-6681.
    View in: PubMed
    Score: 0.021
  66. Incidence of Herpes Zoster Among Children: 2003-2014. Pediatrics. 2019 07; 144(1).
    View in: PubMed
    Score: 0.021
  67. A model for rapid, active surveillance for medically-attended acute gastroenteritis within an integrated health care delivery system. PLoS One. 2018; 13(8):e0201805.
    View in: PubMed
    Score: 0.020
  68. Estimated rates of influenza-associated outpatient visits during 2001-2010 in 6 US integrated healthcare delivery organizations. Influenza Other Respir Viruses. 2018 01; 12(1):122-131.
    View in: PubMed
    Score: 0.019
  69. Myocarditis and pericarditis are rare following live viral vaccinations in adults. Vaccine. 2018 03 14; 36(12):1524-1527.
    View in: PubMed
    Score: 0.019
  70. Rates and risk factors associated with hospitalization for pneumonia with ICU admission among adults. BMC Pulm Med. 2017 Dec 16; 17(1):208.
    View in: PubMed
    Score: 0.019
  71. Maternal and Infant Outcomes After Human Papillomavirus Vaccination in the Periconceptional Period or During Pregnancy. Obstet Gynecol. 2017 09; 130(3):599-608.
    View in: PubMed
    Score: 0.019
  72. Maternal Tdap vaccination and risk of infant morbidity. Vaccine. 2017 06 22; 35(29):3655-3660.
    View in: PubMed
    Score: 0.018
  73. Live attenuated influenza vaccine use and safety in children and adults with asthma. Ann Allergy Asthma Immunol. 2017 04; 118(4):439-444.
    View in: PubMed
    Score: 0.018
  74. Predictors of Breastfeeding Initiation and Maintenance in an Integrated Healthcare Setting. J Hum Lact. 2017 May; 33(2):256-266.
    View in: PubMed
    Score: 0.018
  75. Pregnancy Outcomes after Treatment for Cervical Cancer Precursor Lesions: An Observational Study. PLoS One. 2017; 12(1):e0165276.
    View in: PubMed
    Score: 0.018
  76. Identifying birth defects in automated data sources in the Vaccine Safety Datalink. Pharmacoepidemiol Drug Saf. 2017 Apr; 26(4):412-420.
    View in: PubMed
    Score: 0.018
  77. Acute Demyelinating Events Following Vaccines: A Case-Centered Analysis. Clin Infect Dis. 2016 Dec 01; 63(11):1456-1462.
    View in: PubMed
    Score: 0.017
  78. Maternal Tdap vaccination: Coverage and acute safety outcomes in the vaccine safety datalink, 2007-2013. Vaccine. 2016 Feb 10; 34(7):968-73.
    View in: PubMed
    Score: 0.016
  79. Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis and Influenza Vaccinations in Pregnancy. Obstet Gynecol. 2015 Nov; 126(5):1069-74.
    View in: PubMed
    Score: 0.016
  80. Association of Tdap Vaccination With Acute Events and Adverse Birth Outcomes Among Pregnant Women With Prior Tetanus-Containing Immunizations. JAMA. 2015 Oct 20; 314(15):1581-7.
    View in: PubMed
    Score: 0.016
  81. Demographic characteristics of members of the Vaccine Safety Datalink (VSD): A comparison with the United States population. Vaccine. 2015 Aug 26; 33(36):4446-50.
    View in: PubMed
    Score: 0.016
  82. Evaluation of the association of maternal pertussis vaccination with obstetric events and birth outcomes. JAMA. 2014 Nov 12; 312(18):1897-904.
    View in: PubMed
    Score: 0.015
  83. Receipt of pertussis vaccine during pregnancy across 7 Vaccine Safety Datalink sites. Prev Med. 2014 Oct; 67:316-9.
    View in: PubMed
    Score: 0.015
  84. Comparison of laboratory-confirmed influenza and noninfluenza acute respiratory illness in healthcare personnel during the 2010-2011 influenza season. Infect Control Hosp Epidemiol. 2014 May; 35(5):538-46.
    View in: PubMed
    Score: 0.015
  85. Absence of associations between influenza vaccines and increased risks of seizures, Guillain-Barré syndrome, encephalitis, or anaphylaxis in the 2012-2013 season. Pharmacoepidemiol Drug Saf. 2014 May; 23(5):548-53.
    View in: PubMed
    Score: 0.014
  86. Antibody response to influenza A(H1N1)pdm09 among healthcare personnel receiving trivalent inactivated vaccine: effect of prior monovalent inactivated vaccine. J Infect Dis. 2014 Jun 01; 209(11):1705-14.
    View in: PubMed
    Score: 0.014
  87. Safety of the yellow Fever vaccine: a retrospective study. J Travel Med. 2013 Nov-Dec; 20(6):368-73.
    View in: PubMed
    Score: 0.014
  88. Inactivated influenza vaccine during pregnancy and risks for adverse obstetric events. Obstet Gynecol. 2013 Sep; 122(3):659-67.
    View in: PubMed
    Score: 0.014
  89. Mortality rates and cause-of-death patterns in a vaccinated population. Am J Prev Med. 2013 Jul; 45(1):91-97.
    View in: PubMed
    Score: 0.014
  90. Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children. Vaccine. 2013 May 24; 31(22):2578-83.
    View in: PubMed
    Score: 0.014
  91. Cervical intraepithelial neoplasia grade 3 and adenocarcinoma in situ: comparison of ICD-9 codes and pathology results--Kaiser Permanente, United States, 2000-2005. Cancer Epidemiol Biomarkers Prev. 2013 Jun; 22(6):1129-32.
    View in: PubMed
    Score: 0.014
  92. Predictors of seasonal influenza vaccination during pregnancy. Obstet Gynecol. 2013 Apr; 121(4):741-9.
    View in: PubMed
    Score: 0.014
  93. Maternal safety of trivalent inactivated influenza vaccine in pregnant women. Obstet Gynecol. 2013 Mar; 121(3):519-25.
    View in: PubMed
    Score: 0.014
  94. Prevalence of HPV types in cervical specimens from an integrated healthcare delivery system: baseline assessment to measure HPV vaccine impact. Cancer Causes Control. 2013 Feb; 24(2):403-7.
    View in: PubMed
    Score: 0.013
  95. Trivalent inactivated influenza vaccine and spontaneous abortion. Obstet Gynecol. 2013 Jan; 121(1):159-65.
    View in: PubMed
    Score: 0.013
  96. Secular trends in diagnostic code density in electronic healthcare data from health care systems in the Vaccine Safety Datalink project. Vaccine. 2013 Feb 04; 31(7):1080-5.
    View in: PubMed
    Score: 0.013
  97. Factors predicting completion of the human papillomavirus vaccine series. J Adolesc Health. 2013 Apr; 52(4):427-32.
    View in: PubMed
    Score: 0.013
  98. Patterns in influenza antiviral medication use before and during the 2009 H1N1 pandemic, Vaccine Safety Datalink Project, 2000-2010. Influenza Other Respir Viruses. 2012 Nov; 6(6):e143-51.
    View in: PubMed
    Score: 0.013
  99. The expected emotional benefits of influenza vaccination strongly affect pre-season intentions and subsequent vaccination among healthcare personnel. Vaccine. 2012 May 21; 30(24):3557-65.
    View in: PubMed
    Score: 0.013
  100. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine. 2011 Oct 26; 29(46):8279-84.
    View in: PubMed
    Score: 0.012
  101. H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project. Am J Prev Med. 2011 Aug; 41(2):121-8.
    View in: PubMed
    Score: 0.012
  102. Monitoring vaccine safety using the Vaccine Safety Datalink: utilizing immunization registries for pandemic influenza. Vaccine. 2011 Jul 12; 29(31):4891-6.
    View in: PubMed
    Score: 0.012
  103. Completion and timing of the three-dose human papillomavirus vaccine series among adolescents attending school-based health centers in Oregon. Prev Med. 2011 Jun; 52(6):456-8.
    View in: PubMed
    Score: 0.012
  104. Active surveillance for adverse events: the experience of the Vaccine Safety Datalink project. Pediatrics. 2011 May; 127 Suppl 1:S54-64.
    View in: PubMed
    Score: 0.012
  105. Frequency of medically attended adverse events following tetanus and diphtheria toxoid vaccine in adolescents and young adults: a Vaccine Safety Datalink study. BMC Infect Dis. 2009 Oct 05; 9:165.
    View in: PubMed
    Score: 0.011
  106. Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study. Am J Public Health. 2009 Oct; 99 Suppl 2:S389-97.
    View in: PubMed
    Score: 0.011
  107. Risk of medically attended local reactions following diphtheria toxoid containing vaccines in adolescents and young adults: a Vaccine Safety Datalink study. Vaccine. 2009 Aug 06; 27(36):4912-6.
    View in: PubMed
    Score: 0.011
  108. Varicella vaccination and ischemic stroke in children: is there an association? Pediatrics. 2009 Feb; 123(2):e228-34.
    View in: PubMed
    Score: 0.010
  109. Asthma and farm exposures in a cohort of rural Iowa children. Environ Health Perspect. 2005 Mar; 113(3):350-6.
    View in: PubMed
    Score: 0.008

© 2026 Kaiser Permanente

Your Privacy Choices